Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults

Details

Files
Project Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Technology Review
Project Number:
HE0047 -000

What is the cost-effectiveness of vaccination against respiratory syncytial virus (RSV) for healthy and/or high-risk adults aged 18 years and older compared with no vaccination or other RSV vaccines?

Files

Cost-Effectiveness of Respiratory Syncytial Virus Vaccines for Adults View PDF
Last Updated : February 26, 2024